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Circulating T lymphocytes of patients with prostate cancer have been reported to have functional deficits, including low or
absent z-chain expression. To determine whether these functional impairments could be reversed by prostate specific antigen-
based vaccination therapy, 10 patients treated with recombinant human prostate specific antigen plus GM-CSF and eight
others receiving prostate specific antigen plus oil emulsion in two pilot clinical trials were evaluated prior to and after
vaccination for several immunologic end points, including z-chain expression and cytokine production by circulating T cells as
well as the frequency of T cells able to respond to prostate specific antigen in ELISPOT assays. The flow cytometry assay for
z-chain expression was standardized to allow for a reliable comparison of pre- vs post-vaccination samples. Prior to therapy,
the patients were found to have significantly lower z-chain expression in circulating CD3+ cells and a higher percentage of z-
chain negative CD3+ and CD4+ cells than normal donors. The patients’ peripheral blood mononuclear cells spontaneously
produced more IL-10 ex vivo than those of normal controls. After vaccination, recovery of z-chain expression was observed in
50% of patients in both clinical trials. Also, spontaneous IL-10 secretion by peripheral blood mononuclear cells decreased
following immunotherapy in patients treated with prostate specific antigen and GM-CSF. The frequency of prostate specific
antigen-reactive T cells was detectable in 7 out of 18 patients vs 4 out of 18 patients prior to vaccination. Only one of 18
patients was a clinical responder. The vaccine had stimulatory effects on the patients’ immune system, but post-vaccine
immune recovery could not be correlated to progression-free survival in this small cohort of patients with prostate cancer.
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In patients with advanced cancer, functional impairments of circu-
lating and tumour-infiltrating lymphocytes have been frequently
reported. For example, lymphocytes of cancer patients often show
reduced proliferative and/or cytotoxic responses, have an altered
cytokine profile and typically exhibit reduced/absent expression
of TcR-associated signal-transduction molecules (reviewed Alving
et al, 1993). Expression of one of these molecules, the z-chain,
was shown to be decreased in T cells of patients with a variety
of solid tumours, including renal, colorectal, gastric, pancreatic,
cervical and prostate cancer (Whiteside, 1999). Decreased z-chain
expression in circulating T cells before therapy appeared to corre-
late with the presence of advanced disease in patients with cancer
(Matsuda et al, 1995; Zea et al, 1995). Furthermore, low or absent
z-chain expression in tumour-infiltrating T-cells was identified as
an independent and significant predictor of shorter survival in
patients with advanced oral carcinoma (Reichert et al, 1998).
Decreased z-chain expression reflects the diminished functional
competency of T cells. Both tumour-infiltrating and circulating T
cells in patients with cancer have been found to express less or
no z and to have functional defects (Rabinowich et al, 1998; Reich-
ert et al, 2000).
It has been reported that non-specific immunotherapy with
cytokines or adoptively-transferred autologous lymphocytes plus
IL-2 results in a recovery of z-chain expression in peripheral T cells
of some of the treated patients (Bukowski et al, 1998; Gratama et
al, 1999; Kono et al, 1998; Tartour et al, 1995). To investigate the
possibility that active specific immunotherapy can normalize z-
chain expression in T cells of patients with prostate cancer and lead
to improved T-cell functions, we studied a cohort of patients
receiving PSA-based vaccines. We have previously shown that the
administration of a PSA-based vaccine resulted in the generation
of PSA-reactive T cells in this cohort of patients with surgically
incurable prostate cancer (Meidenbauer et al, 2000).
In the present study, we evaluated lymphocytes, which were
obtained from the same patients prior to and after vaccination,
for changes in z-chain expression in parallel with monitoring the
frequency of PSA-reactive T cells in the peripheral circulation
and cytokine profiles of the T cells. Our results indicate that in
some of these patients, PSA-based vaccination resulted in the
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restoration of impaired z-chain expression and generation of PSA-
reactive circulating T cells.
MATERIALS AND METHODS
Prostate specific antigen (PSA)
Recombinant human PSA was produced in insect cells infected
with baculovirus containing the open reading frame for PSA.
Sequence analysis of the PCR amplification product revealed a
single nucleotide difference of C to A at the position 643 compared
with the published sequence (Lundwall and Lilja, 1987), corre-
sponding to an amino acid change from Pro to Glu. Due to the
baculovirus cleavage site, the amino terminus contained two extra
amino acids, Asp and Leu. Culture supernatants containing recom-
binant (r) PSA were purified by affinity chromatography, using a
murine monoclonal anti-PSA antibody (clone HB 8527, purchased
from ATCC, Rockville, MD, USA) in a good-manufacturing prac-
tice (GMP) facility at the TSI Washington Laboratories (Rockville,
MD, USA). This recombinant PSA was used to prepare the vaccine.
Liposomal PSA vaccine (JBT 1001)
Recombinant PSA at the concentration of about 100 mg ml71 was
added to the lyophilized lipids and incubated at 48C. The lipo-
somes were diluted in 20 mM Tris-glycine-buffer-150 mM sodium
chloride, pH 7.4 and centrifuged at 30 000 g for 30 min to remove
unencapsulated PSA. Liposomes were manufactured under GMP
conditions, as previously described (Alving et al, 1993; Wassef et
al, 1994). PSA-containing liposomes (1.2 ml) were placed in 2 ml
vaccine vials (Wheaton, Millville, NJ, USA) and designated as
JBT 1001 vaccine. Prior to administration to patients, JBT 1001
was tested for pyrogenicity, safety, residual solvents immunogeni-
city as well as sterility. Toxicology studies in rabbits were also
performed.
Patients
Eighteen patients with prostate carcinoma, who participated in two
pilot vaccination trials, are evaluated in this immunological study.
The first pilot trial was performed in 11 patients treated by subcu-
taneous (s.c.) administration of JBT 1001 with locally-injected GM-
CSF (125 mg daily for 5 days). In the second trial, 11 patients
received intramuscular (i.m.) injections of JBT 1001 emulsified in
light mineral oil as adjuvant. To enter these pilot trials, patients
had to meet the following eligibility criteria: histologically docu-
mented prostate cancer; surgically incurable disease, an ECOG
performance status of 0 and 1 and an estimated life expectancy
of more than 6 months. Furthermore, they had to have completed
surgery or chemotherapy/ radiation at least 4 or 6 weeks, respec-
tively, before starting the vaccine regimen. Hormonal treatment
was permitted. All patients had a hematocrit of at least 32%,
adequate hepatic function (bilirubin and SGOT 536upper limit
of normal) and renal function (BUN and creatinine 41.56upper
limit of normal). The blood PSA-values were required to be
550 ng ml71, and all the patients had the ability to be sensitized
against dinitrofluorobenzene (DNFB). Steroid therapy, active
second malignant disease (except basal squamous cell carcinoma
of the skin) or cerebral metastases were exclusion criteria. All
patients gave informed consent, and the study was conducted at
Lankenau Hospital (Wynnewood, PA, USA) following approval
by the Institutional Review Board. An investigational new drug
(IND) application was on file with FDA. Prior to vaccination,
the patients had a complete physical examination, chest X-ray,
bone scan and CT-scan of the abdomen and pelvis. Peripheral
blood was obtained for CBC, chemistry panel, PSA and immuno-
logical studies on days 0, 30, 60 and 90. Additional blood samples
were drawn 60 days after the delivery of vaccination boosts.
Patients were sensitized to DNFB prior to entry on the protocol.
The delayed-type hypersensitivity (DTH) response to human PSA
was tested on day 90. Table 1 provides an overview of the patient
characteristics.
The 18 of 22 vaccinated patients, who were included in this immu-
nologic evaluation, remained on study at least until day 90. Four of
the 22 patients did not remain in the study until day 90 and, there-
fore, were not included in the immunologic evaluation (two with
disease progression, two withdrew because of personal reasons).
Seven normal donors age-matched with the patients (median age
73 years; range from 61 to 80 years) as well as 12 normal donors
recruited from among the laboratory personnel (median age 33 years;
range from 30 to 49 years) were included in the study.
Vaccination schema
In the trial with GM-CSF as adjuvant (the 200 series), patients
received 1 ml JBT 1001 containing PSA (100 mg) and lipid A
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Table 1 Characteristics of patients with prostate carcinoma who were evaluated in this
study
Age DTH Site of Clinical response Progression free
Patient (years) (mm) disease at day 90 survival (months)
201 65 0 Bone PD 0
202 60 30630 LN, Bone PD 0
203 67 0 Prostate S 28
205 66 0 Prostate S 435
206 62 57639 Prostate S 429
207 58 29627 Prostate S 428
208 73 30625 Prostate, LN S 11
209 52 35635 Prostate, bone S 17
210 80 35635 Prostate, bone S 429
211 64 52640 Prostate S 15
401 67 30630 Prostate, bone S 429
402 70 70645 Prostate, bone PR 11
403 74 15615 Prostate S 17
404 70 35635 Prostate, bone S 429
405 75 0 Prostate S 29
408 72 35630 Prostate, bone S 14
410 70 30620 Prostate, bone S 7
411 71 30625 Prostate S 17
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(200 mg) on days 0, 30 and 60 subcutaneously (s.c.). One hundred
and twenty-five mg of recombinant GM-CSF (Immunex Corp.,
Seattle, WA, USA) was injected s.c. into the vaccination site on
days 0 – 4, 30 – 34, and 60 – 64.
In the vaccination trial using oil emulsion (the 400 series), JBT
1001 was emulsified with light mineral oil to form oil-in-water
emulsion and delivered intramuscularly (i.m.). Each ml of the
vaccine contained 90 mg PSA, 180 mg lipid A and 0.1 ml of mineral
oil emulsified in a syringe fitted with a 3-way stopcock. The immu-
nization schedule was as described above.
In both trials, patients with stable disease at day 90 after vacci-
nation received booster vaccinations every 60 days until disease
progression.
Collection and storage of blood specimens
Prior to vaccine administration, patients underwent leukapheresis,
and peripheral blood mononuclear cells (PBMC) were harvested
on Ficoll-Hypaque, washed, counted, resuspended in the freezing
medium and cryopreserved in liquid N2 in cryovials, each contain-
ing 20 – 306106 cells. Following the initial vaccination sequence
(days 0, 30, 60) peripheral blood specimens were obtained on days
90 (Post), 150 (Boost no. 1), 210 (Boost no. 2), 270 (Boost no. 3)
and 330 (Boost no. 4). The cryopreserved PBMC were thawed just
prior to the initiation of the assays, diluted into warm RPMI-
medium (Gibco Life-Technologies, Grand Island, NY, USA)
supplemented with 20% (v/v) foetal calf serum (FCS; Gibco Life-
Technologies), and washed twice with RPMI medium. Viability
was checked using a Trypan blue dye and was found to be
490% in all instances.
Determination of z-chain expression by two-colour flow
cytometry
All assays were performed on cryopreserved and thawed PBMC.
Aliquots of cells (2.56106 ml71 in 200 ml of PBS) were dispensed
into tubes and incubated for 30 min with 5 ml aliquots of one of
the following antibodies: CD3-FITC, CD4-FITC, CD8-FITC or
isotype IgG as control (all purchased from Becton Dickinson,
San Jose, CA, USA). After the incubation period, the cells were
washed twice with PBS and then fixed with 0.25% (w/v) parafor-
maldehyde for 10 min at room temperature. The cells were again
washed twice with PBS and then once with cold saponin (0.1%
w/v in PBS+0.1% w/v BSA) solution. The cells were then permea-
bilized for 30 min on ice in 100 ml of the saponin solution.
Aliquots (10 ml) of TcRz – PE or isotype-IgG (Immunotech,
Marseilles, France) were added at the same time. Following the
incubation period, the cells were washed twice with saponin and
then once with PBS. Flow cytometry analysis was performed imme-
diately on FACScan (Becton Dickinson). At least 10 000 events
were acquired for data analyses.
The analysis was performed using the Lysis II program. The
lymphocyte gate was established based on FCS/SCC. Lymphocytes
were then backgated to CD3+, CD4+ or CD8+ populations and
their mean fluorescence intensity (MFI) determined. In addition
to MFI, the percentage of z-negative cells was determined. Based
on the cutoff level established by using the MFI values obtained
with the isotype control, it was possible to classify the T cell subsets
as z-positive and z-negative. Pre- and post-therapy samples were
always tested in the same assay.
Aliquots of PBMC obtained from one normal donor were cryo-
preserved and tested each time the assay was run to control for
inter-assay variability. To further standardize the assay and to
determine the intra-assay and the inter-individual variability of z-
chain expression in T cells, PBMC were obtained from six normal
male donors and were tested in triplicate in assays performed on
different days. To estimate intra-individual (biologic) variability,
PBMC samples were obtained from six male donors at three differ-
ent times separated by at least 1 month, and the cryopreserved
serial samples were tested together in one assay.
Separation of PBMC into CD4+ and CD8+ T cells
PBMC were separated into CD4+ and CD8+ T cells by positive
immunoselection, using magnetic beads (MiniMacs, Miltenyi
Biotec, Auburn, CA, USA) according to the manufacturer’s recom-
mendations. The purity of the selected CD4+ or CD8+ T-cell
fractions was checked by flow cytometry.
Generation of dendritic cells (DC)
Leukapheresis products obtained from each patient prior to entry
on the protocol were processed as previously described (Meiden-
bauer et al, 2000). Dendritic cells were generated from
cryopreserved PBMC in 7 day cultures, using IL-4 and GM-CSF
as described by us before (Meidenbauer et al, 2000). On day 6,
10 mg ml71 of purified human PSA (Cortex Biochem, San Lean-
dro, CA, USA) or 10 mg ml71 of ovalbumin (Sigma) were added
to the DC culture for a period of 12 – 16 h. For some patients,
non-pulsed DC were used as control DC. The cells were then
harvested by incubating them with cold Hanks’ Balanced Salt Solu-
tion (Gibco Life Technologies) for 15 – 30 min. After two washing
steps, the DC were adjusted to the required concentrations, based
on the content of large cells and used as APC.
ELISPOT assay for IFN-g production
The ELISPOT assay was performed exactly as previously described
by us (Meidenbauer et al, 2000). Briefly, T lymphocytes (CD4+ or
CD8+) separated by positive selection on immunobeads were
placed in wells of 96-well ELISPOT plates at 105 cells per well.
Then, autologous DC pulsed with PSA or ovalbumin (as a control
antigen) were added. Control wells containing PBMC and DC not
pulsed with any antigen were also set up. The assay was usually run
in triplicate or quadruplicate. After 24 h incubation of the plates in
a humidified atmosphere of CO2 in air at 378C, the plates were
developed to visualize the spots as previously described (Meiden-
bauer et al, 2000). The spots were counted by computer-assisted
image analysis (ELISPOT 4.143, Zeiss, Jena, Germany). The
number of specific spots was calculated by subtracting control
values (spots counted for DC not pulsed with PSA and co-
incubated with PBMC) from experimental values. The number of
spots in control wells was either 0 or 1 for all specimens in this
series. The assay was standardized as described earlier (Asai et al,
2000; Meidenbauer et al, 2000), and its CV was 15% with n=19.
The sensitivity of the assay was estimated to be 1/105 cells (Asai
et al, 2000).
Cytokine production assays
After thawing, 100 ml aliquots of PBMC were plated at the concen-
tration of 16106 cells ml71 into wells of 96-well U-bottom plates
(Linbro, ICN Biomedicals, Auroram CA, USA). One hundred ml
aliquots of RPMI+ 10% FCS (Gibco Life Technologies) with or
without PHA (20 mg ml71) (Sigma) were added to each well. After
48 h of incubation in a humidified atmosphere of 5% CO2 in air at
378C, the supernatants were removed, centrifuged once to remove
cell debris and stored at 7808.
ELISA for IL-2 and IL-10
IL-2 and IL-10 levels in the supernatants were determined by
ELISA (R&D systems) according to the manufacturer’s recommen-
dations. Each sample was tested in duplicate, and the standard
dose-responsive curves were established using the WHO cytokine
standards.
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Statistical analysis
z-chain expression for patients was compared to that of normal
healthy controls by the exact Wilcoxon test. If multiple assay
results were available for normal controls, the median was used.
Fisher’s exact test was used to compare proportions of response
between the different treatment groups. The overall change with
treatment was tested with a signed rank test applied to the differ-
ences between pre-and-post treatment z-chain expression.
Individual patients were classified as either increasing, not changing
or decreasing the z-chain expression in T cells with treatment. An
individual patient increase or decrease in z-chain expression was
defined as exceeding a 95% confidence bound calculated from
repeated measurements of normal controls who were assumed to
represent normal biologic variability between measurements.
Correlations between immunologic parameters and clinical para-
meters were calculated using Spearman’s rank test.
RESULTS
Standardization of the assay for z-chain expression
z-chain expression in T lymphocytes was evaluated by flow cyto-
metry, measuring both mean fluorescence intensity (MFI) and
the percentage of z-chain-negative cells in the population (Kuss
et al, 1999). Cryopreserved cells were used based on earlier
comparisons made between fresh and cryopreserved PBMC (i.e.,
each sample was split and tested fresh as well as after cryopreserva-
tion). These comparisons indicated no significant differences in z-
chain expression between the samples (data not shown). Inter-assay
variability was determined for both MFI and the percentage of z-
chain-negative cells, using cells of one normal donor which were
cryopreserved, thawed and tested for z-chain expression every time
the assay was performed on 10 different days. The MFI values for
z-chain were: 332+32 (s.e.m.) in CD3+ T cells, 423+35 in CD4+
T cells and 298+20 in CD8+ T lymphocytes. Because of this
substantial inter-assay variability, we routinely test all pre- and
post-vaccine samples of one patient in the same assay. The mean
percentage of z-chain-negative T cells was less than 1% in this
donor’s cells, too low to be reliably used for determination of
the assay variability.
To establish intra-assay variability for z-chain expression, six
PBMC samples, each obtained from a different donor, were tested
in triplicate in flow cytometry assays performed on different days.
The results of triplicate determinations for each donor were very
tight (i.e., the intraclass correlations were 40.8 for MFI), indicat-
ing that intra-assay variability was excellent for both MFI and the
per cent of z-negative cells.
In addition, cells of all six donors were repeatedly obtained at
three time points separated by 1 month, and at each time point
were tested together in one assay in order to determine biologic
(intra-individual) variability in z-chain expression (Figure 1). This
was important, because the patients’ cells were sampled at different
time points, even when the pre- and post-vaccine samples were
tested in the same assay. The intra-individual (biologic) variations
for three different samples obtained from the same normal donor
over a period of 3 months and tested in the same assay were
considerable, as shown in Figure 1. We assumed that they would
be equally substantial for the patients’ cells. Therefore, to define
a significant change in z expression (i.e., a change that was larger
than expected and, therefore, not due to assay variability) for an
individual, we set a cutoff value for MFI of the z-chain as well
as for the percentage of z-chain-negative cells. This cutoff value
was defined to be greater than half the width of the 95% confi-
dence interval determined for intra-individual variability as
described above. Thus, a change of 62 MFI units for z in CD3+
cells, 113 units for z in CD4+ cells and 72 units for z in CD8+ cells
detected in an individual sample was considered to be significantly
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Figure 1 Intra-individual variability of MFI for z-chain expression and the per cent of z-chain-negative cells in CD3+, CD4+ and CD8+ T cell subsets
obtained from six normal donors (C1 – 6). The samples were drawn at three different time points 1 month apart. PBMC were cryopreserved and tested
in the same assay to establish the biologic variation within each individual evaluated over a 3 month period. The solid line connects the median values. Of
note, the percentages of z-chain-negative T cells are very low in normal controls, except for CD8+ T cells in C5.
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greater than normal biologic variability for this individual. For the
percentage of z-chain-negative T cells in CD3+, CD4+ and CD8+
populations, these values were 0.7, 0.7 and 2.6%, respectively.
Patients were scored as responders in terms of z-chain expression
when a significant change, as described by the above criteria, in
the MFI or the percentage of z-negative cells occurred following
vaccination.
Differences in z expression between patients and controls
The analyses for z-chain expression were performed in CD3+,
CD4+ and CD8+ lymphocytes obtained from patients and controls
(Figure 2). Although the control group included seven age-matched
and 12 younger individuals, no significant difference in z expres-
sion was observed between the older and younger donors in this
and other studies performed in our laboratory (data not shown).
The two subgroups were, therefore, combined into one control
group, and z-chain expression was compared in T cells of patients
and normal donors. Both the MFI for z and per cent z-negative
cells were significantly lower for CD3+ T cells in patients with pros-
tate cancer than in controls (P=0.0374). As a group, these patients
with prostate cancer had a significantly decreased percentage of z-
positive CD3+ and z-positive CD4+ T cells, but not of the CD8+ T
cells, when compared to normal donors (Figure 2). It should be
noted that in controls, only a very small proportion of z-negative
T cells was detected (usually 51%), while in the patients, the
percentage of z-negative T cells varied broadly from none to more
than 70% (Figure 2b).
Also, as illustrated in Figure 3, two distinct populations of T
cells were identifiable in the circulation of some of the patients:
z-positive and z-negative (e.g., patient no. 401). In other patients,
nearly all T cells were z-positive (e.g., patient no. 411), a situation
comparable to what is typically observed in T cells of normal
donors. The percentage of z-negative cells allowed us a better
discrimination than MFI between these two groups of patients.
For this reason, we selected to present the flow cytometry data
both as MFI for z expression and as percentages of z-negative cells
(Figure 2a and b).
Changes in expression of z-chain after vaccination
The comparison of pre- and post-therapy samples, using both
parameters (MFI and the percentage of z-chain-negative T cells)
and applying the criteria established to rule out biologic variability,
indicated that up-regulation of z expression occurred in T cells of a
proportion of patients (Figure 4). In six patients (no’s. 205, 206,
210, 401, 402 and 403) a significant decrease in the percentage z-
chain-negative CD3+ cells was accompanied by a significantly
increased MFI for the z-chain after vaccination (Table 2). These
changes were observed in both CD4+ and CD8+ T cell sub-popula-
tions (Figure 4).
When the patients included in the 200 and 400 series were sepa-
rately examined for z expression in T cells prior to and after
vaccination therapy, it appeared that the more extensive changes
were observed in the 400 series (Figure 5b). However, when pre-
and post-vaccine changes in the percentage of z-negative T cells
were compared, 50% of patients in both series showed significantly
increased z-chain expression (Table 2). Also, the patients with the
highest per cent of z-negative T cells prior to therapy showed the
largest per cent decrease after treatment.
Frequency of PSA-reactive T cells
To determine the frequency of PSA-reactive T cells in the periph-
eral circulation, PBMC were enriched in CD4+ and CD8+ cells and
then tested in 24 h ELISPOT assays. In order to correlate ELISPOT
results with z-chain expression, the frequency of PSA-responsive T
cells was measured directly in PBMC without in vitro stimulation
(IVS), since in vitro culture could restore the impaired z-chain
expression (Rabinowich et al, 1996). As reported previously by
us, the assay is very sensitive, capable of detecting 1 out of
100 000 positive cells and has a negligible non-specific background,
when PBMC are used as responders (Asai et al, 2000).
Although the observed frequencies of PSA-reactive T cells in the
circulation of patients were generally low, as previously reported by
us (Meidenbauer et al, 2000), in 7 out of 18 patients a detectable number
of precursor T cells responsive to PSA was present (Table 2). In three of
thesesevenpatients, thefrequencyofPSA-reactiveTcells increasedafter
vaccination. In 3 out of 18 patients (nos. 201, 401 and 402), we found a
detectable number of PSA-reactive T cells before treatment (see Table
2). In age- and sex-matched normal donors, only one out of seven tested
samples had a detectable frequency of PSA-reactive T cells (1 out of
10 000 in CD4+ T cells).
It is also interesting to note that 3 out of 4 of the patients who
had negative DTH responses to PSA on day 90 (nos. 201, 202 and
405), had detectable but very low frequencies of PSA-reactive T
cells in the circulation after the vaccine administration.
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Figure 2 Comparisons of the z-chain expression in T cells and T-cell
subsets between patients and healthy controls are presented as box-
whisker plots. The white bar represents the median; the box represents
the interquartile range; the whiskers represent 1 times the interquartile
range; and the single lines show the outliers. Nineteen healthy controls
were compared with 18 patients with prostate cancer. (A), MFI for z-chain
expression and (B), percentages of z-chain-negative cells in patients and
healthy controls are shown. The P values were calculated by the exact Wil-
coxon test.
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Cytokine production assays
To get additional information about the immune status of the
patients, levels of IL-2 and IL-10 secreted by PBMC spontaneously
or after stimulation with the mitogen, PHA, were measured in 43
patient samples and six control PBMC specimens obtained from
sex- and age-matched normal donors. Spontaneous IL-2 produc-
tion was detected in 5 out of 18 pre-therapy samples by ELISA
(data not shown). In contrast, spontaneous IL-10 (45 pg ml71)
production by PBMC was observed in 11 out of 18 pre therapy
samples (Figure 6). Only 1 out of 6 normal PBMC spontaneously
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Figure 3 Flow cytometry dot plots for z-chain expression in two representative patients with prostate carcinoma. The gate was set on CD3+ T cells. In
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produced IL-10, while the cytokine profile of the patients was
skewed toward IL-10 production prior to vaccination.
PHA-stimulated production by PBMC of IL-10 and IL-2 was
evaluated as a measure of general immunocompetence. No signifi-
cant vaccine-related changes were observed in stimulated IL-10 or
IL-2 release (Figure 6), although in the 200 series, a trend toward
lower IL-10 production and higher IL-2 release was observed after
vaccination.
Spontaneous production of IL-10 by the patients’ PBMC was
found to be significantly decreased after vaccination only in the
200 vaccine series (Figure 6; P50.01). In the two patients (nos.
401 and 402) whose PBMC spontaneously secreted high levels of
IL-10 (4500 pg ml71) prior to treatment, the level of IL-10
secreted by PBMC dropped to 10 pg ml71 after vaccination
(Figure 6). Interestingly, in these two patients, low z-chain expres-
sion observed prior to therapy increased significantly after
treatment, and an increase in the number of PSA-reactive T cells
was observed as well.
Correlations between the immunological parameters and
clinical outcome
Attempts were made to correlate immunological parameters with
the clinical outcome. Progression free survival (PFS) was selected
as a clinical end point, because 16 out of 18 patients were still alive
(March, 2000), and among them only one partial response was
observed.
In this cohort of patients, no correlation between DTH in
response to PSA after therapy and PFS was evident. Also, no
correlations could be established between PFS and z-chain expres-
sion before therapy, changes in z-chain expression after therapy or
an increased frequency of PSA-reactive T cells. However, the three
patients (nos. 401, 402, 411), who mounted a significant T-cell
responses after treatment with the vaccine, as determined by
ELISPOT and a DTH response to PSA, and the only patient
(no. 402) with a documented PR (improvement in bone scintigra-
phy) also showed significant increases in z-chain expression after
therapy.
DISCUSSION
Two small pilot vaccination trials with PSA performed in patients
with advanced prostate cancer allowed us an opportunity to exam-
ine changes in several immunologic variables during therapy. The
study focused on T-cell responses in order to assess the impact
of therapy on both PSA-specific and non-specific immunity. The
rationale for the study was based on the hypothesis that successful
vaccination is associated with upregulation of functions in immune
cells, particularly their PSA-related activity. Thus, the presence of
functional, activated T cells, which are thought to be largely
responsible for anti-tumour effects, is a prerequisite for the efficacy
of the vaccine.
One goal of this study was to determine whether z-chain expres-
sion in circulating T cells could be altered by the vaccine. We
expected that the PSA vaccine plus oil emulsion or GM-CSF as
adjuvants may have general immunostimulatory effects, leading
to increased z-expression in T cells. Immunotherapy with cytokines
or autologous lymphocytes was previously reported to increase z-
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Table 2 Changes in z expression, IL-10 production and the frequency of PSA-reactive T cells in
patients with prostate cancer prior to and after vaccination with JBT 1001a
CD3+ CD3+ IL-10 spont. Freq. PSA-reactive T cellsb
Pt D MFI for z D% z negative D CD4 CD8
200 Series
201 49 70.3 0 Pre 1/12 500 0
Post 1/14 286 1/12 500
202 718 0 77 Pre 0 0
Post 1/20 000 0
203 54 77* 740 — —
205 96* 73* 710 — —
206 98* 77* 0 — —
207 5 2 720 — —
208 78 2 737 — —
209 775 71 0 Pre 0 1/11 110
Post 0 1/9090
210 174* 715* 74
211 55 74* 76 — —
400 Series
401 186* 738* 7546 Pre 1/9090 0
Post 1/4000 1/2564
402 225* 767* 7503 Pre 1/10 000 1/6666
Post 1/3845 1/3845
403 112* 73* 2 — —
404 713 2 717 — —
405 31 724* 3 Pre 0 0
Post 1/16 666 0
408 734 71 0 — —
410 723 0 NDc — —
411 202* 0 17 Pre 0 0
Post 1/2500 0
aThe significance of changes from pre- to post-vaccine values was established using the cut-off based on deter-
minations of intra-individual variability, as described in Results. Significant changes (D) are indicated by asterisks.
bThe frequencies of PSA-reactive T cells (either CD4+ or CD8+) were determined in ELISPOT assays perfor-
med as described in Materials and methods. Only data for the patients who had detectable frequencies of PSA-
reactive T cells in PBMC are listed, although T cells of all 18 patients were evaluated in ELISPOT assays. The
frequencies were calculated from the number of specific spots/105 T cells plated/well. cND=not done.
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chain expression (Bukowski et al, 1998; Gratama et al, 1999; Kono
et al, 1998; Tartour et al, 1995). After the PSA vaccine, recovery of
z-(i.e., decreased per cent of z-negative cells) was observed in 50%
of our patients regardless of the adjuvant used. These data suggest
that the vaccine containing GM-CSF was not more immunostimu-
latory than that containing PSA + oil emulsion.
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Recent studies have considered the possibility that cancer-related
signalling defects in lymphocytes, e.g., low or absent z-chain
expression, encountered in patients with advanced disease might
contribute to limited responses or the lack of responses frequently
seen with immunologically-based therapies (Bukowski et al, 1998;
Gratama et al, 1999; Kuss et al, 1999; Rabinowich et al, 1996).
Our patients with prostate cancer evaluated prior to vaccination,
showed significantly decreased expression of the z-chain in circulat-
ing T lymphocytes compared to normal controls, a finding similar
to that previously reported by Healy et al (1998). However, not all
T cells had low z and not all patients with prostate cancer had T
cells with decreased z expression (Figure 3). In a subset of these
patients, the percentage of z-chain-negative T cells was significantly
increased in the peripheral circulation compared to healthy volun-
teers, who had very few z-chain-negative T cells, except in one
person’s CD8+ cells (Figure 1). It appears that a gradient of z-chain
loss exists in the patient population, ranging from normal z expres-
sion to its absence in only some or most of circulating T cells. The
per cent of z-negative cells in patients was significantly decreased
among CD3+ and CD4+, but not CD8+ cells, although some indi-
vidual patients had very high proportions of z-negative CD8+ cells
never seen in controls. Because z expression is lower in CD8+ than
CD4+ T cells (Kuss et al, 1999) and is also more variable in CD8+
T cells of normal donors and patients alike, the observed lack of
significance for CD8+ cells is attributed to a small sample size.
Several distinct mechanisms seem to contribute to a rapid turn-
over of z (reviewed by Whiteside, 1999) and may be responsible for
differences in z expression in T cells of patients with cancer
reported in the literature (Bukowski et al, 1998; Cardi et al,
1997; Deakin et al, 1999; Healy et al, 1998; Kuss et al, 1999).
Although the mechanism(s) responsible for z-down-regulation in
cancer remains unclear, it appears to be tumour-related (Gastman
et al, 1999; Reichert et al, 1998; Whiteside, 1999). The degree of z
impairment is greater in TIL than in PBL in individual patients
(Matsuda et al, 1995; Rabinowich et al, 1996). Normal T cells
co-incubated with tumour cells or their supernatants down-regu-
late z-chain expression (Dworacki et al, 2001; Maccalli et al,
1999). Recent data indicate that tumour-derived circulating factors,
such as 14 kD protein described by Taylor et al. (2001) or tumour
associated HLA-class I molecules (Maccalli et al, 1999) could
mediate this effect. The tumour microenvironment is rich in
H2O2 or NO, which are secreted by activated macrophages in situ
(Kono et al, 1996) or activated granulocytes in the circulation of
patients with cancer (Schmielau and Finn, 2001). Oxygen metabo-
lites have been shown to interfere with T cell functions and to
down-regulate z (Kono et al, 1996). Also, the presence of chronic
antigenic stimulation in cancer patients could lead to activation-
induced cell death (AICD) and depletion of tumour-specific T cells
by apoptosis (Dworacki et al, 2001; Horiguchi et al, 1999). We
previously reported that the z-chain is a target for caspases in
apoptosing lymphocytes, an observation which links the loss of z
with apoptosis (Gastman et al, 1999). The low frequency of PSA-
specific T cells in the circulation of our patients seems to be consis-
tent with this last hypothesis.
The biologic and clinical significance of the z-chain recovery in
cancer patients treated with immunotherapy is also not clear.
While previous studies demonstrated a significant relationship
between z expression in T cells and patient survival (Reichert el
al, 1998; Zea et al, 1995), the relevance of z expression in T cells
of patients with prostate cancer or its clinical and prognostic
importance is unknown. In this study, no significant correlations
could be established between z-chain expression before or after
therapy and DTH responses to PSA or an increase in the frequency
of PSA-reactive T cells after therapy and progression-free survival.
Nevertheless, some interesting insights were obtained. Three
patients (all in the 400 series) showed significant up-regulation
of z expression as well as a substantial increase in PSA-reactive T
cells after therapy (nos. 401, 402 and 411). All three had positive
DTH to PSA. The only patient who had a documented PR to
the vaccine (no. 402) was in this subgroup. The two patients with
PD had relatively normal z expression before and after therapy.
Among 15 patients with s.d., there were eight with PFS 420
months and seven with PFS 520 months. In the former group,
6 out of 8 (75%) showed significant z-up-regulation vs 3 out of
7 (42%) in the latter. While this difference is not statistically signif-
icant, it suggests that z expression may have some relationship to
clinical responses, although larger studies will be necessary to deter-
mine its clinical significance.
The frequency of PSA-reactive precursor cells in the patients’
circulation after therapy ranged from 1 out of 2500 to 1 out of
20 000, as assessed by ELISPOT and was comparable to the
frequencies reported by Lewis et al. (2000) for cancer patients trea-
ted with peptide-based vaccines. But in 11 out of 18 patients no
detectable PSA-reactive T cells were present either before or after
vaccination, although all but four of the patients were able to
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Figure 6 Cytokine secretion by the patients’ PBMC. Either spontaneous
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and 402 have high pre-vaccination levels of IL-10, which decreased after
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200 series are statistically significant at P50.01.
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respond to PSA by DTH after vaccination. This implies that func-
tions of T cells, as measured in in vitro assays, were suppressed in
patients with prostate cancer. One clue may be the relatively high
levels of IL-10, considered to be an immunosuppressive cytokine
(Moore et al, 1993) and an independent prognostic factor in solid
tumours (DeVita et al, 2000), which was spontaneously produced
by patients’ PBMC. After therapy, spontaneous production of IL-
10 decreased in general, but most dramatic decreases were seen
in the two patients (nos. 401 and 402) who had higher frequencies
of PSA-specific T cells after vaccination therapy.
In summary, our results indicate that a PSA vaccine was able to
restore impaired z-chain expression and to generate specific T cells
in some patients with advanced prostate cancer. Although a corre-
lation between clinical outcome and immunological endpoints
could not be established in this small cohort of patients, monitor-
ing of z-chain expression, the frequency of PSA specific T cells and
the cytokine profile may be able to define patients who are capable
of mounting a cellular response against the tumour. Other studies
seeking a correlation between immunologic and clinical responses
to vaccines in patients with prostate cancer report conflicting
results (Lodge et al, 2000; Murphy et al, 2000). In one of these
studies the percentage of z-positive cells within the CD3+ popula-
tion was identified as one of 10 variables predictive of clinical
responses in patients with metastatic disease (Murphy et al,
2000). The findings we report provide an encouragement that by
using immune markers such as z expression, it might be possible
in the future to single out patients who are most likely to benefit
from vaccine-based therapies.
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